Modern Active Surveillance in Prostate Cancer: A Narrative Review

Trent A. Pattenden; Dhanika Samaranayke; Andrew Morton; Wee Loon Ong; Declan G. Murphy; Elizabeth Pritchard; Susan Evans; Jeremy Millar; Venu Chalasani; Prem Rashid; Matthew Winter; Ian Vela; David Pryor; Stephen Mark; Nathan Lawrentschuk; Isaac A. Thangasamy

doi:10.1016/j.clgc.2022.09.003

Modern Active Surveillance in Prostate Cancer: A Narrative Review

Trent A. Pattenden, Dhanika Samaranayke, Andrew Morton, Wee Loon Ong, Declan G. Murphy, Elizabeth Pritchard, Susan Evans, Jeremy Millar, Venu Chalasani, Prem Rashid, Matthew Winter, Ian Vela, David Pryor, Stephen Mark, Nathan Lawrentschuk, Isaac A. Thangasamy

Research output: Contribution to journal › Review Article › Other › peer-review

1 Citation (Scopus)

Abstract

The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection criteria and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection criteria recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection.

Original language	English
Pages (from-to)	115-123
Number of pages	9
Journal	Clinical Genitourinary Cancer
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.clgc.2022.09.003
Publication status	Published - Feb 2023

Keywords

Active surveillance
Intermediate risk prostate cancer
Low risk prostate cancer
MRI
Risk stratification

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clgc.2022.09.003

Cite this

Pattenden, T. A., Samaranayke, D., Morton, A., Ong, W. L., Murphy, D. G., Pritchard, E., Evans, S., Millar, J., Chalasani, V., Rashid, P., Winter, M., Vela, I., Pryor, D., Mark, S., Lawrentschuk, N., & Thangasamy, I. A. (2023). Modern Active Surveillance in Prostate Cancer: A Narrative Review. Clinical Genitourinary Cancer, 21(1), 115-123. https://doi.org/10.1016/j.clgc.2022.09.003

@article{9bfdd2f19ddb4607a63c0c96d65249ca,

title = "Modern Active Surveillance in Prostate Cancer: A Narrative Review",

abstract = "The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection criteria and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection criteria recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection.",

keywords = "Active surveillance, Intermediate risk prostate cancer, Low risk prostate cancer, MRI, Risk stratification",

author = "Pattenden, {Trent A.} and Dhanika Samaranayke and Andrew Morton and Ong, {Wee Loon} and Murphy, {Declan G.} and Elizabeth Pritchard and Susan Evans and Jeremy Millar and Venu Chalasani and Prem Rashid and Matthew Winter and Ian Vela and David Pryor and Stephen Mark and Nathan Lawrentschuk and Thangasamy, {Isaac A.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = feb,

doi = "10.1016/j.clgc.2022.09.003",

language = "English",

volume = "21",

pages = "115--123",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "1",

}

Pattenden, TA, Samaranayke, D, Morton, A, Ong, WL, Murphy, DG, Pritchard, E , Evans, S , Millar, J, Chalasani, V, Rashid, P, Winter, M, Vela, I, Pryor, D, Mark, S, Lawrentschuk, N & Thangasamy, IA 2023, 'Modern Active Surveillance in Prostate Cancer: A Narrative Review', Clinical Genitourinary Cancer, vol. 21, no. 1, pp. 115-123. https://doi.org/10.1016/j.clgc.2022.09.003

TY - JOUR

T1 - Modern Active Surveillance in Prostate Cancer

T2 - A Narrative Review

AU - Pattenden, Trent A.

AU - Samaranayke, Dhanika

AU - Morton, Andrew

AU - Ong, Wee Loon

AU - Murphy, Declan G.

AU - Pritchard, Elizabeth

AU - Evans, Susan

AU - Millar, Jeremy

AU - Chalasani, Venu

AU - Rashid, Prem

AU - Winter, Matthew

AU - Vela, Ian

AU - Pryor, David

AU - Mark, Stephen

AU - Lawrentschuk, Nathan

AU - Thangasamy, Isaac A.

PY - 2023/2

Y1 - 2023/2

N2 - The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection criteria and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection criteria recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection.

AB - The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection criteria and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection criteria recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection.

KW - Active surveillance

KW - Intermediate risk prostate cancer

KW - Low risk prostate cancer

KW - MRI

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85143623768&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2022.09.003

DO - 10.1016/j.clgc.2022.09.003

M3 - Review Article

C2 - 36443163

AN - SCOPUS:85143623768

VL - 21

SP - 115

EP - 123

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -

Modern Active Surveillance in Prostate Cancer: A Narrative Review

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this